Vertical Sleeve Gastrectomy and Lifestyle Modification for the Treatment of Non-Alcoholic Steatohepatitis

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age30-70
SponsorUniversity of Minnesota

About this trial

Participants meeting study entry criteria are randomized with equal probability to one of two study groups: (1) Lifestyle modification or (2) Vertical Sleeve Gastrectomy (VSG) with Iifestyle modification, followed for 12 months. The primary goal for the trial is to determine if the investigators can recruit, randomize, and retain participants to perform invasive and non-invasive measurements of NASH and fibrosis, deliver lifestyle modification and demonstrate the safety of VSG. The investigators wish to also understand which of these two interventions is more effective in achieving, 12 months after entry into the trial, a reduction in NAS composed of the non-weighted scores: (1) steatosis 0-3 (2) Inflammation 0-3 and (3) ballooning 0-2. Secondary goals include comparing the two treatment groups for changes in other measured outcomes including MRI assessments of intrahepatic triglyceride and liver elasticity and serum markers. As a pilot study, a sample size of 20 in each group should offer significant information as to the difference in NAS score reduction between to two groups and achieve adequate power to distinguish clinically significant changes in the primary and secondary outcome measures. These data support the overarching objective i.e. to provide evidence that a larger, longer-term clinical outcomes trial is feasible. A goal is for a longer term follow up for 5 years to assess the durability of treatment effects and treatment differences.

Eligibility criteria

Qualifiers

Age 30 to 70 years at eligibility visit.

Diagnosed with NASH with a total NAS ≥ 4 including a ballooning score of at least 1

Diagnosed with T2DM or prediabetes, HbA1c< 9%

Body Mass Index (BMI): 35.0-60.0 kg/m2 at eligibility visit.

Disqualifiers

Cardiovascular event (myocardial infarction, acute coronary syndrome, coronary artery angioplasty or bypass, stroke) in the past six months.

Current evidence of congestive heart failure, angina pectoris, or symptomatic peripheral vascular disease.

Pulmonary embolus or thrombophlebitis in the past six months.

Cancer of any kind (except basal cell skin cancer or cancer in situ) unless documented to be disease-free for five years.

Trial design

Treatments tested in this trial

  • Vertical Sleeve Gastrectomy
  • Lifestyle Modification Counseling

Treatment groups

48 Participants
are divided into 2 treatment groups

Sponsors and collaborators